USE OF MYCOPHENOLATE MOFETIL (MMF) IN A CASE WITH SEVERE HENOCH- SCHÖNLEIN NEPHRITIS.

Renal involvement is one of the most serious sequela of Henoch-Schönlein purpura. The presence of proteinuria (nephritic range) and hematuria is also associated with progression to renal insufficiency. In fifty percent of patients who display a combination of nephritis-nephrotic symptoms, end-stage disease develops. Pharmacologic treatments are controversial, and more research needs to be done to clarify therapeutic regimens.

A five years old child with clacic signs and symptoms of Henoch-Schönlein purpura and sever renal involvement (combination of nephritis-nephrotic syndrome) was treated succesfuly by Mycophenolate mofetil. This case was resistant to methyl prednisolon and cyclophosphamid pulse.

Mycophenolate mofetil is an immunosuppressive agent which is used in many autoimmune disorders such as lupus nephritis, vasculitis, necrotizing glomerulonephritis, corticosteroid resistant glomerunephritis and IgA nephropathy, but there are no enough data on the use of mycophenolate mofeti in complications of Henoch-Sch nlein diseases. Herein, we report successful use of Mycophenolate mofetil in a case with severe Henoch Schönlein- nephritis resistant to both methylprednisolone and cyclophosphamid pulse.